Thoracic Cancer (MSK, Nat Commun 2021)

Summary

Thoracic Cancer (MSK, Nat Commun 2021) is a study catalogued by cBioPortal DataHub under the cancer-type code lung. EvidenceHelix groups it with multiple or not classified from the title studies.

Study description

Targeted sequencing of tumor and PDX thoracic samples.

Text as published in the source's study metadata.

Citation & PubMed

Rebecca et al. Nat Commun. 2022

Linked PubMed records: PMID 35440124

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

lung_pdx_msk_2021

Short name

PDX_IMPACT (2021)

Source cancer-type code

lung

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Rebecca et al. Nat Commun. 2022

• PubMed record 35440124 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Thoracic PDX (MSK, Provisional)

  Targeted sequencing of thoracic PDX lines to characterize genetic alterations in 318 tumor/normal pairs via MSK-IMPACT. This cohort is a PDX tracker of all lung cancer PDX generated at MSK that have been through IMPAC…

  Multiple or not classified from the titleMSK studiesSource code lung

• Appendiceal Cancer (MSK, J Clin Oncol 2022)

  Targeted sequencing of 273 appendiceal tumor/normal pairs via MSK-IMPACT platform.

  Multiple or not classified from the titleMSK studiesSource code apadPubMed 1

• BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is comple…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)

  Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)

  Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)

  Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)

  Targeted sequencing of 1,007 cerebrospinal fluid circulating tumor DNA from patients with central nervous system tumors using MSK-IMPACT and their matched normals.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.